<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990740</url>
  </required_header>
  <id_info>
    <org_study_id>EGN_2017_22</org_study_id>
    <nct_id>NCT03990740</nct_id>
  </id_info>
  <brief_title>Myofibroblastic Transformation Secondary to Epithelial-stromal Interactions in the Keratoconus</brief_title>
  <acronym>MYKE</acronym>
  <official_title>Myofibroblastic Transformation Secondary to Epithelial-stromal Interactions in the Keratoconus (MYKE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Keratoconus is characterized by a thinning of the cornea, which causes a decrease in visual
      acuity due to astigmatism.

      Publications suggest that keratoconus is linked to chronic inflammation (increase in
      pro-inflammatory cytokines and metalloproteinases (MMP). Direct epithelial-stromal
      interactions (D-ESI) have a role in the induction of metalloproteinases (MMP) and the
      differentiation of fibroblasts into myofibroblasts via an EMMPRIN membrane glycoprotein
      (extracellular matrix membran MMP inducer - CD 147). On a healthy cornea, EMMPRIN's effects
      are prevented by a lack of contact between epithelial and stromal cells through a basement
      membrane, which is altered in the keratoconus The hypothesis is that stromal thinning of the
      keratoconus could be related to increased expression of EMMPRIN by epithelial and stromal
      cells (resulting in increased MMP synthesis), with a preponderance at the most deformed
      areas.

      The main objective is to demonstrate a transformation of fibroblasts to myofibroblasts in the
      corneal stroma of keratoconus patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Logistical difficulties : protocol never finalized nor submitted
  </why_stopped>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">May 12, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of alpha-SMA's (Smooth Muscle Actin) messenger RNA expression evaluated by quantitative PCR (RT-qPCR) in corneal stroma in keratoconus patients compared to non-keratoconus controls</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients suffering from keratoconus and requiring a first optical corneal transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients with an indication of orbital exenteration operation due to an orbital tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corneal sampling</intervention_name>
    <description>Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Keratoconus patients requiring first optical corneal transplantation and controls with
        indication of orbital exenteration due to an orbital tumor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the cases :

             - Suffering from keratoconus and requiring a first optical corneal transplant

          -  For the controls:

               -  Orbital exenteration operation due to an orbital tumor

               -  Absence of any anomaly of the ocular surface observed during the slit lamp
                  examination at the last preoperative consultation

        Exclusion Criteria:

          -  For the cases:

               -  Keratoconus patient requiring a tectonic corneal transplant

               -  Known pregnancy, or breastfeeding

          -  For the controls:

               -  History of orbital radiotherapy

               -  History of corneal surgery

               -  History of corneal surface tumour

               -  Eye surface abnormality noted in the preoperative period

               -  Known keratoconus

               -  Known pregnancy, or breastfeeding

               -  Secondary exclusion if a keratoconus is diagnosed during the immunohistochemical
                  analysis by visualization of Bowman membrane interruption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metalloproteinase</keyword>
  <keyword>Glycoprotein</keyword>
  <keyword>Cornea</keyword>
  <keyword>Direct epithelial-stromal interactions</keyword>
  <keyword>Fibroblasts</keyword>
  <keyword>Myofibroblasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

